Genmab A/S ADS (GMAB) Stock
NASDAQ · GMAB
35.17
Fundamentals
Market cap
$21.72B
Price / Earnings ratio
27.6x
Price / Sales ratio
5.3x
Price / Book ratio
3.6x
Return on assets
9.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
NeutralGMABSeptember 27, 2026
MarketBeatNeutral
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
GMAB

MarketBeat
Genmab A/S Q2 Earnings Call Highlights
NeutralGMABAugust 6, 2026
MarketBeatNeutral
Genmab A/S Q2 Earnings Call Highlights
GMAB

Business Wire
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NeutralGMABJuly 23, 2026
Business WireNeutral
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
GMAB

Zacks Investment Research
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
NeutralGMABJuly 7, 2026
Zacks Investment ResearchNeutral
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
GMAB
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
4B3B1B0
Debt & Balance Sheet
Total assets
Total liabilities
2025
15B10B5B0
Revenue to Profit
2025$3.7B
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$963.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
NeutralGMABSeptember 27, 2026
MarketBeatNeutral
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
GMAB

MarketBeat
Genmab A/S Q2 Earnings Call Highlights
NeutralGMABAugust 6, 2026
MarketBeatNeutral
Genmab A/S Q2 Earnings Call Highlights
GMAB

Business Wire
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NeutralGMABJuly 23, 2026
Business WireNeutral
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
GMAB

Zacks Investment Research
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
NeutralGMABJuly 7, 2026
Zacks Investment ResearchNeutral
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
GMAB

Business Wire
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
NeutralGMABJuly 6, 2026
Business WireNeutral
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
GMAB

Business Wire
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NeutralGMABJune 13, 2026
Business WireNeutral
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

Business Wire
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
NeutralGMABJune 11, 2026
Business WireNeutral
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
GMAB

Business Wire
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
NeutralGMABApril 13, 2026
Business WireNeutral
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
GMAB

Zacks Investment Research
Is the Options Market Predicting a Spike in Genmab Stock?
NeutralGMABFebruary 13, 2026
Zacks Investment ResearchNeutral
Is the Options Market Predicting a Spike in Genmab Stock?
GMAB

Stocktwits
Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug
NeutralGMABJanuary 16, 2026
StocktwitsNeutral
Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug
GMAB
About Genmab A/S ADS
No description available.
SectorHealthcare
IndustryBiotechnology
Employees3,119
CEODr. Jan G.J. van de Winkel Ph.D.
IPO DateJun 1, 2009
HeadquartersCopenhagen, Denmark
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 1961 |
| Mr. Anthony Pagano CPA | Executive VP & CFO | 1978 |
| Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer | 1968 |
| Mr. Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 1971 |
| Mr. Christopher Cozic | Executive VP & Chief People Officer | 1978 |
| Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer | 1971 |
| Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 1975 |
| Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer | 1958 |
| Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines | 1973 |
| Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director | 1973 |
Fundamentals
Valuation
Market cap$21.72B
Price-to-sales ratio5.26
Price-to-book value3.65
Price-earnings ratio27.60
Return on Equity15.00%
Return on Sales36.00%
Return on Assets9.00%
PEG ratio4.36
Earnings Per Share
Earnings Per Share$1.28
Income Statement
Average volume1,979,665
EBITDA$1.50B
1 year high (52w)$35.66
1 year low (52w)$23.62
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Buy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$41.67
Est return
19.30%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.2 | +3.4 | -14.0 | +4.1 | ||||||||
| 2022 | -14.1 | -3.4 | +6.3 | -4.0 | -13.1 | +8.2 | +6.6 | +1.2 | -9.9 | +13.9 | +21.3 | -8.6 |
| 2023 | -9.0 | -4.0 | +2.1 | +9.2 | -4.0 | -3.4 | +8.4 | -4.5 | -8.1 | -17.1 | +9.2 | -0.4 |
| 2024 | -14.0 | -1.4 | +2.1 | -8.5 | -1.9 | -12.8 | +13.8 | -1.9 | -11.1 | -7.6 | -4.7 | -4.4 |
| 2025 | -6.3 | +18.7 | -14.7 | +13.3 | +0.1 | -5.1 | +4.5 | +14.2 | +18.5 | -9.9 | +12.7 | -1.9 |
| 2026 | +2.5 | -11.5 | -9.5 | -2.6 | -0.5 | +7.9 | +4.5 | +15.6 | +6.1 |



